Background
==========

Osteosarcoma is the most common kind of malignancy in musculoskeletal tumors and has the characteristic of forming early lung metastases and unfavorable survival \[[@b1-medscimonit-23-5892]\]. Although in the past decades, surgery in combination with neoadjuvant and postoperative chemotherapy has extended the overall survival time for osteosarcoma patients, there are still controversies regarding the appropriate dose of chemotherapy agents \[[@b2-medscimonit-23-5892]\]. In addition, once osteosarcoma becomes chemo-resistant, there are few therapeutic strategies available. In high-grade cases, the puzzling question arises as to whether patients should receive more aggressive chemotherapy regimens or radiotherapy. Also, numerous efforts have been made to assess second-line chemotherapy agents for refractory cases; however, there is limited methodology available to evaluate the response rate of conventional chemotherapy except for the evaluation of necrosis \[[@b3-medscimonit-23-5892],[@b4-medscimonit-23-5892]\]. If there were reliable biomarkers that could predict osteosarcoma susceptibility or prognosis, clinicians could apply aggressive regimens or radiotherapy for high-risk patients.

Insulin-like growth factor 1 (IGF-1) is a member of the IGF family, a family of insulin-related proteins or peptides \[[@b5-medscimonit-23-5892]\]. IGF-1 is involved in the regulation of cell survival, proliferation, and differentiation. The downstream signaling pathways include the MAPK pathway, PI3K-Akt pathway, and NF-κB pathway \[[@b6-medscimonit-23-5892],[@b7-medscimonit-23-5892]\]. The gene locus that encodes IGF-1 is located on chromosome 12. Given the fact that IGF-1 is involved in regulating mitogenesis and anti-apoptosis, the role of the IGF family members in osteosarcoma tumorigenesis or progression is still poorly understood. The receptor of IGF-1 (IGF-1R) has been found to be overexpressed in multiple musculoskeletal sarcomas, including osteosarcoma \[[@b8-medscimonit-23-5892]\]. Increasing evidence indicates that IGF-1 related pathways are involved in osteosarcoma progression \[[@b9-medscimonit-23-5892],[@b10-medscimonit-23-5892]\]. However, there is still controversy regarding the prognostic value of IGF-1R or IGF-1 expression in osteosarcomas. For instance, Wang et al. reported that higher expression of IGF-1R was associated with poorer survival \[[@b10-medscimonit-23-5892]\], while van de Luijtgaarden et al. showed that IGF-1R seemed to be correlated with better overall survival \[[@b11-medscimonit-23-5892]\]. Larger cohort studies are needed to reach a more accurate conclusion; however, the low incidence of osteosarcoma severely limits large studies. Thus, studies utilizing blood samples or other easy-to-obtain data are of great value.

Single nucleotide polymorphisms (SNPs) have been validated to be correlated with the risk and prognosis of solid malignancies. However, SNPs role in osteosarcomas are still elusive because of the rarity of the disease. As emerging studies revealed the prognostic role played by SNPs in tumors, it will be important to evaluate genetic polymorphisms of given genes in osteosarcoma \[[@b3-medscimonit-23-5892]\]. SNPs of IGF-1 have been proven to be associated with susceptibility and outcomes of some cancers, including prostate cancer, colorectal cancer, and breast cancer. Hence, we conjectured that IGF-1 polymorphisms might be associated with osteosarcoma tumorigenesis.

We collected peripheral blood samples from 173 osteosarcoma cases and 175 healthy controls to analyze IGF-1 polymorphisms and to reveal the relationship between IGF-1 SNPs and osteosarcomas. In this case-control study, we analyzed five IGF-1 SNPs (rs6214, rs6218, rs35767, rs5742612, and rs5742714) and tried to validate the hypothesis that IGF-1 polymorphisms might be associated with susceptibility and progression of osteosarcoma.

Material and Methods
====================

Ethics approval
---------------

This case-control study involving patients was approved by the ethical committee board of the two institutions. Signed informed consents were obtained from all participants or their legal guardians.

Osteosarcoma cases and controls
-------------------------------

There were 173 primary osteosarcoma individuals and 175 tumor-free controls involved in this case-control study. All the study patients were Chinese Han people. All osteosarcoma cases were pathologically diagnosed from October 2009 to March 2012. Before performing neoadjuvant chemotherapy, blood samples from individuals were collected and preserved in liquid nitrogen. All osteosarcoma cases received established therapeutic strategies including essential neoadjuvant chemotherapy, surgical excision, and postoperative chemotherapy. Surgeries were performed by experienced orthopedic surgeons and all osteosarcoma individuals were followed for at least 60 months. Tumor-free controls were trauma cases and were matched to osteosarcoma individuals by age and sex. All the clinical materials were reviewed from saved clinical records.

DNA extraction
--------------

Total DNA was isolated from peripheral blood by proteinase K digestion and phenol-chloroform method. A Blood DNA Extraction Kit from Qiagen was utilized for DNA isolation. In brief, blood samples were mixed with proteinase K and cultured for 10 minutes at 55°C, and then centrifuged to remove drops from the inside of the lid. Then 200 μL ethanol was added and mixed by pulse-vortex, and then centrifuged. This mixture was applied to the QIAamp Mini spin column from the kit. After centrifuging at 6,000 g for one minute, 500 μL Buffer AW2 was added and then centrifuged at 20,000 g for three minutes. Extracted DNA was used for further genotyping.

SNP genotyping
--------------

We reviewed the HapMap data and picked out frequent SNPs (frequency \>5% in the Chinese Han people). Five SNPs (rs6214, rs6218, rs35767, rs5742612, and rs5742714) were genotyped and evaluated. Sequence Detection Systems software on an ABI StepOnePlus system (Thermo Fisher Scientific) was used for data collection and analyses. Primers and probes for TaqMan assays were designed online on the ABI Assay-by-Design services. We used 384-well plates from ABI, and all samples were run in triplicate. Two technicians independently performed SNP genotyping in a blinded manner. The amplification conditions were two minutes at 50°C and 10 minutes at 95°C, followed by 40 cycles at 95°C for 15 seconds and at 60°C for 60 seconds.

Haplotype analysis
------------------

Computational haplotyping method was used for haplotype analysis. The five tagging SNPs were analyzed on SHEsis system (*<http://analysis.bio-x.cn/myAnalysis.php>*) to find haplotypes with frequencies over 3%.

Statistical analysis
--------------------

The Pearson's χ^2^ test was used to evaluate the differences in frequency distributions of characteristics including age, sex, and Enneking stage. Selected variables and genotypes of *IGF-1* changes were compared between the osteosarcoma individuals and the tumor-free controls. Odds ratios (ORs) and 95% confidential intervals (95% CIs) were calculated to evaluate the association between the five selected tagging SNPs and the susceptibility or prognosis of osteosarcoma. Unconditioned logistic regression analysis was preformed to evaluate crude ORs, and subsequently adjusted for age and sex. The Hardy-Weinberg equilibrium was also evaluated using Pearson's χ^2^ test. A value of *p*\<0.05 was considered statistically significant. All statistical analyses were two-sided and performed by SPSS 21.0.

Results
=======

Clinical characteristics
------------------------

Clinical information of all included osteosarcoma individuals and tumor-free controls are displayed in [Table 1](#t1-medscimonit-23-5892){ref-type="table"}. There were 92 male osteosarcoma cases and 81 female osteosarcoma cases. The medium age and range of osteosarcoma cases and control cases was 15.35±2.91 years and 15.76±3.40 years, respectively, with no statistical difference for age (*p*=0.352) or sex (*p*=0.521). The Enneking GTM System was used for clinical staging \[[@b12-medscimonit-23-5892]\]. In the osteosarcoma group, there were 21 early-stage cases (stage I) and 152 late-stage cases (stage II or III). Among the 173 osteosarcoma cases, 24 individuals underwent amputation and 149 cases underwent limb salvage. During the five-year-follow-up, 83 cases developed lung metastases.

IGF-1 SNP rs6218 was correlated with the risk of osteosarcoma
-------------------------------------------------------------

The pooled data of the five evaluated SNPs (rs6214, rs6218, rs35767, rs5742612, and rs5742714) are shown in [Table 2](#t2-medscimonit-23-5892){ref-type="table"}. In the tumor-free control individuals, the genotype distributions of the evaluated five tagging SNPs were all within Hardy-Weinberg equilibrium (*p*=0.552, 0.710, 0.225, 0.189, and 0.312, respectively). In IGF-1 SNP rs6218, when the TT homozygote genotype was set as the reference group, the TC genotype was found to be statistically significantly elevated for the risk of osteosarcoma (TC versus TT: crude OR=1.51, 95% CI=1.15--1.82, *p*=0.002; adjusted OR=1.50, 95% CI=1.13--1.82, *p*=0.002). Furthermore, the TT homozygote genotype was also found to be associated with the risk of osteosarcoma (CC versus TT: crude OR=1.42, 95% CI=1.10--1.77, *p*=0.009; adjusted OR=1.43, 95% CI=1.09--1.88, *p*=0.008). In addition, in the dominant model (TC+CC), a statistical difference was also revealed (TC+CC versus TT: crude OR=1.39, 95% CI=1.11--1.76, *p*=0.003; adjusted OR=1.38, 95% CI=1.08--1.78, *p*=0.004). In the recessive model (TT+TC), when compared with the CC homozygote genotype, a statistical difference was also found (TT+TC versus CC: crude OR=1.07, 95% CI=1.03--1.39, *p*=0.017; adjusted OR=1.10, 95% CI=1.05--1.40, *p*=0.015).

The other four tagging SNPs (rs6214, rs35767, rs5742612, and rs5742714) did not show potential correlations with osteosarcoma susceptibility in Chinese Han individuals.

rs6218 was associated with the Enneking stage and metastatic risk of osteosarcoma
---------------------------------------------------------------------------------

Pooled data on tumor primary location, Enneking stage, operation technique, and metastasis of osteosarcoma was used to study the correlations between the five selected SNPs and osteosarcomas ([Table 3](#t3-medscimonit-23-5892){ref-type="table"}). For rs6218, the frequency of the genotype TC and CC at late Enneking stages (51.97% and 3.29%, respectively) were significantly higher when compared with early-stage cases (38.09% and 9.53%, respectively), and a statistical difference in distribution was revealed (*p*=0.007). Furthermore, the evaluation of tumor metastasis also showed statistically significant results. The genotype TC displayed significantly higher frequency (62.22%) in metastasized cases when compared with metastasis-free cases (53.01%), and the difference in distributions was statistically significant (*p*=0.002). This data indicated that rs6218 polymorphisms were associated with late Enneking stages and higher risk of lung metastasizing.

The possible confounding variables (Enneking stages and metastasis) are shown in [Tables 4](#t4-medscimonit-23-5892){ref-type="table"} and [5](#t5-medscimonit-23-5892){ref-type="table"}. No statistical differences were found.

Haplotype analyses showed statistical differences between osteosarcoma cases and control cases
----------------------------------------------------------------------------------------------

The evaluation of the five SNPs revealed eight frequent (frequency \>3%) haplotypes: GCGGT, CGCGA, CCCTT, CAACA, CAGGG, CCGGG, CCGGT, and GCGGC ([Table 6](#t6-medscimonit-23-5892){ref-type="table"}). The haplotype CGCGA showed a statistically significantly difference between the osteosarcoma cases and tumor-free control cases (*p*=0.008, OR 1.787, 95% CI=1.535--2.208). The other seven haplotypes did not reveal any differences between osteosarcoma cases and cancer-free control cases.

Discussion
==========

Osteosarcoma is a rare malignancy, with morbidity about five per million population annually \[[@b13-medscimonit-23-5892]\]. The low morbidity rate severely restricts clinical sample-based studies. Although accumulating studies have reported some potential biological biomarkers for osteosarcoma, further studies are needed to improve the accuracy of those markers. In addition, attempts to find alternative therapeutic strategies, especially non-surgical strategies, have been refractory for osteosarcomas \[[@b14-medscimonit-23-5892],[@b15-medscimonit-23-5892]\]. Until now, there have been no satisfactory strategies that include first-line regimens in the clinical care setting of osteosarcomas. Thus, finding new prognostic markers that can predict osteosarcoma risks or outcomes for conventional therapy would be of great value.

Emerging studies have revealed genetic factors that are potentially associated with osteosarcoma carcinogenesis and/or progression. However, one of the most important factors for improving the clinical value of biomarkers is improving the method used to evaluate the markers. Genetic polymorphisms, which can be studied based on blood samples and evaluated by PCR, are good biomarker candidates based on available methodology. In osteosarcoma, some studies have demonstrated promising prognostic roles for biomarkers including *NAT2* \[[@b16-medscimonit-23-5892]\], *WWOX* \[[@b17-medscimonit-23-5892]\], and *TCF21* \[[@b18-medscimonit-23-5892]\]. However, in most circumstances, using only one genetic polymorphism factor is not considered reliable due to the limited number of cohorts available that restricts accuracy. IGF-1 is produced by the liver and by some malignant cells, and is believed to be involved in osteosarcoma tumorigenesis. Recently, epidemiologic and experimental studies have revealed the value of IGF-1 genetic polymorphisms in predicting tumor risk and prognosis. In a study involving a large cohort of prostate cancer cases (5,887 cases), the IGF signaling pathway was found to be associated with prostate cancer mortality \[[@b19-medscimonit-23-5892]\]. Other studies have also emphasized the prognostic role of IGF-1. In a study recruiting 110 colorectal cancer cases and 137 breast cancer cases, the genetic polymorphisms of IGF-1 were evaluated. The authors reported that IGF-1 SNPs were correlated with cancer risk and prognosis \[[@b20-medscimonit-23-5892]\]. In addition, another recent study provided some evidence that targeting IGF-1R might suppress osteosarcoma progression, highlighting the role that the IGF-1 family plays in osteosarcoma \[[@b21-medscimonit-23-5892]\].

Our study was based on a large number of cases to evaluate whether genetic polymorphisms in IGF-1 was associated with osteosarcoma risk and progression. Five candidate SNPs were genotyped and analyzed; and rs6218 was found to be associated with significantly higher osteosarcoma susceptibility. Moreover, rs6218 was discovered to be correlated with metastasis potential of osteosarcoma, indicating that alterations in this SNP were associated with poorer prognosis of osteosarcoma. According to our results, if a patient suffering from osteosarcoma has worse phenotypes of rs6218, which indicates higher risk of metastasis potential, clinicians should consider using more aggressive therapeutic strategies and perform more frequent follow-ups. However, although the other four study SNPs were not related to osteosarcoma risk or progression in our study, they have been found to be associated with some other malignancies. Thus, we could not reach a conclusion that the other four SNPs were irrelevant to osteosarcoma. In addition, we also performed haplotype analyses. The frequency of haplotype CGCGA was statistically significantly different between the osteosarcoma cases and the tumor-free control cases.

There were limitations to our study. We could not avoid inherent bias as all the blood samples were preserved and obtained from one institution. Furthermore, the sample size weakened the power of statistical analyses, especially for the results of homozygotic cases. Some homozygotic types only had a very small number of cases. Expanded studies that recruit more osteosarcoma cases would help improve the efficacy of the prognostic effect of IGF-1 genetic polymorphisms.

Conclusion
==========

In conclusion, to the best of our knowledge, this is the first study to report that IGF-1 genetic polymorphisms were associated with osteosarcoma susceptibility and progression, especially metastasis. Thus, *IGF-1* rs6218 SNP polymorphisms can be considered valuable prognostic biomarkers for osteosarcoma.
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###### 

General characteristics.

  Variables                             Osteosarcoma cases \[n (%)\]   Tumor-free control n (%)\]   *P*
  ------------------- ----------------- ------------------------------ ---------------------------- -------
  Age                 Mean ±SD (year)   15.35±2.91                     15.76±3.40                   0.352
  Gender              Male              92 (53.18)                     95 (54.28)                   0.521
  Female              81 (46.82)        80 (45.72)                                                  
  Location            Trunk             18 (10.40)                                                  
  Limbs               155 (89.60)                                                                   
  Enneking stages     IA or IB          21 (12.13)                                                  
  IIA or IIB or III   152 (87.87)                                                                   
  Operation           Amputation        24 (13.87)                                                  
  Limb salvage        149 (86.13)                                                                   
  Metastasis          Yes               83 (47.98)                                                  
  No                  90 (52.02)                                                                    

###### 

Logistic regression analyses of associations between *IGF-1* rs6214, rs6218, rs35767, rs5742612, and rs5742714 polymorphisms and risk of osteosarcoma.

  IGF-1 genotype   Cases (n=173)   Controls (n=175)   Crude OR (95%Cl)   *P*     Adjusted OR (95%Cl)   *P*                                                                             
  ---------------- --------------- ------------------ ------------------ ------- --------------------- ----------------------------------------------------------- ------------------- -----------------------------------------------------------
  rs6214 G/A                                                                                                                                                                           
   GG              49              28.32              51                 29.14   1.00                                                                              1.00                
   GA              84              48.55              86                 49.14   1.22 (0.73--1.59)     0.287                                                       1.21 (0.72--1.58)   0.293
   AA              40              23.13              38                 21.72   1.29 (0.83--1.42)     0.311                                                       1.30 (0.82--1.44)   0.301
   GA+AA           124             71.68              124                70.86   1.13 (0.79--1.35)     0.233                                                       1.13 (0.79--1.36)   0.225
   GG+GA           133             76.87              137                78.28   1.00                                                                              1.00                
   AA              40              23.13              38                 21.72   1.10 (0.57--1.25)     0.310                                                       1.12 (0.58--1.29)   0.320
  rs6218 T/C                                                                                                                                                                           
   TT              90              52.02              110                62.86   1.00                                                                              1.00                
   TC              69              39.88              60                 34.29   1.51 (1.15--1.82)     0.002[\*](#tfn1-medscimonit-23-5892){ref-type="table-fn"}   1.50 (1.13--1.82)   0.002[\*](#tfn1-medscimonit-23-5892){ref-type="table-fn"}
   CC              14              8.10               5                  2.85    1.42 (1.10--1.77)     0.009[\*](#tfn1-medscimonit-23-5892){ref-type="table-fn"}   1.43 (1.09--1.88)   0.008[\*](#tfn1-medscimonit-23-5892){ref-type="table-fn"}
   TC+CC           83              47.98              249                87.06   1.39 (1.11--1.76)     0.003[\*](#tfn1-medscimonit-23-5892){ref-type="table-fn"}   1.38 (1.08--1.78)   0.004[\*](#tfn1-medscimonit-23-5892){ref-type="table-fn"}
   TT+TC           159             91.90              165                57.69   1.00                                                                              1.00                
   CC              14              8.10               121                42.31   1.07 (1.03--1.39)     0.017[\*](#tfn1-medscimonit-23-5892){ref-type="table-fn"}   1.10 (1.05--1.40)   0.015[\*](#tfn1-medscimonit-23-5892){ref-type="table-fn"}
  rs35767 C/T                                                                                                                                                                          
   CC              63              36.41              66                 37.71   1.00                                                                              1.00                
   CT              86              49.71              83                 47.43   0.85 (0.48--1.22)     0.331                                                       0.84 (0.47--1.21)   0.341
   TT              24              13.88              26                 14.86   1.12 (0.77--1.53)     0.561                                                       1.10 (0.72--1.50)   0.560
   CT+TT           110             63.59              109                62.29   0.91 (0.60--1.38)     0.620                                                       0.92 (0.63--1.40)   0.610
   CC+CT           149             86.12              149                85.14   1.00                                                                              1.00                
   TT              24              13.88              26                 14.86   1.23 (0.89--1.91)     0.320                                                       1.22 (0.86--1.94)   0.317
  rs5742612 T/C                                                                                                                                                                        
   TT              76              43.93              83                 47.43   1.00                                                                              1.00                
   TC              79              45.66              76                 43.43   0.73 (0.48--1.09)     0.220                                                       0.75 (0.49--1.12)   0.222
   CC              18              10.41              16                 9.14    1.10 (0.77--1.83)     0.441                                                       1.10 (0.76--1.83)   0.440
   TC+CC           97              56.07              92                 52.57   0.96 (0.73--1.11)     0.125                                                       0.92 (0.71--1.07)   0.121
   TT+TC           155             89.59              159                90.86   1.00                                                                              1.00                
   CC              18              10.41              16                 9.14    1.25 (0.80--1.90)     0.109                                                       1.24 (0.76--1.88)   0.108
  rs5742714 G/C                                                                                                                                                                        
   GG              112             64.74              115                65.71   1.00                                                                              1.00                
   GC              53              30.64              50                 28.57   0.60 (0.41--1.25)     0.520                                                       0.60 (0.40--1.22)   0.518
   CC              8               4.62               10                 5.72    0.89 (0.50--1.52)     0.771                                                       0.91 (0.51--1.53)   0.750
   GC+CC           61              35.26              60                 34.29   0.82 (0.71--1.39)     0.472                                                       0.85 (0.75--1.39)   0.463
   GG+GC           165             95.38              165                94.28   1.00                                                                              1.00                
   CC              8               4.62               10                 5.72    1.21 (0.87--1.60)     0.229                                                       1.20 (0.86--1.62)   0.219

Statistically significant (P\<0.05).

###### 

Correlations between genotype frequencies of *IGF-1* rs6218T/C and clinical features in osteosarcoma individuals.

  Variables            n     TT n (%)     TC n (%)     CC n (%)     *P*
  -------------------- ----- ------------ ------------ ------------ ---------
  Location                                                          
   Trunk               18    10 (55.56)   7 (38.89)    1 (5.55)     0.106
   Limbs               155   83 (53.55)   55 (35.48)   17 (10.97)   
  Enneking stages                                                   
   IA or IB            21    11 (52.38)   8 (38.09)    2 (9.53)     0.007\*
   IIA or IIB or III   152   68 (44.74)   79 (51.97)   5 (3.29)     
  Operation                                                         
   Amputation          24    12 (50.00)   10 (41.67)   2 (8.33)     0.082
   Limb salvage        149   72 (48.32)   70 (49.98)   7 (4.70)     
  Metastasis                                                        
   Yes                 83    38 (45.78)   44 (53.01)   1 (1.21)     0.002\*
   No                  90    29 (32.22)   56 (62.22)   5 (5.56)     

Statistically significant (*P*\<0.05).

###### 

Confounding variables (Enneking stages).

  Confounding variables   IA or IB cases \[n (%)\]   IIA or IIB or III cases \[n (%)\]   *P*          
  ----------------------- -------------------------- ----------------------------------- ------------ -------
  Age                     Mean ±SD (year)            14.57±3.16                          15.02±2.86   0.772
  Gender                  Male                       11 (52.38)                          80 (53.69)   0.102
  Female                  10 (47.62)                 79 (46.31)                                       

###### 

Confounding variables (metastasis).

  Confounding variables   Metastasis cases \[n (%)\]   Non-metastasis cases \[n (%)\]   *P*          
  ----------------------- ---------------------------- -------------------------------- ------------ -------
  Age                     Mean ±SD (year)              14.66±3.02                       15.03±3.12   0.581
  Gender                  Male                         44 (53.01)                       49 (54.44)   0.312
  Female                  39 (46.99)                   41 (45.56)                                    

###### 

Haplotype analyses.

  Haplotype   Cases (n=173)   Controls (n=175)   *P*                                                         OR (95% Cl)
  ----------- --------------- ------------------ ----------------------------------------------------------- ----------------------
  GCGGT       5.71 (0.033)    4.91 (0.028)       0.133                                                       1.125 (0.610--1.733)
  CGCGA       7.27 (0.042)    21.35 (0.122)      0.008[\*](#tfn3-medscimonit-23-5892){ref-type="table-fn"}   1.787 (1.535--2.208)
  CCCTT       15.40 (0.089)   16.10 (0.092)      0.525                                                       0.611 (0.375--1.196)
  CAACA       17.65 (0.102)   19.78 (0.113)      0.093                                                       1.190 (0.733--1.574)
  CAGGG       6.06 (0.035)    7.18 (0.041)       0.109                                                       0.688 (0.472--1.337)
  CCGGG       7.27 (0.042)    8.58 (0.049)       0.331                                                       0.835 (0.577--1.395)
  CCGGT       12.11 (0.070)   13.83 (0.079)      0.115                                                       0.815 (0.606--1.070)
  GCGGC       21.63 (0.125)   23.63 (0.135)      0.227                                                       1.182 (0.785--1.545)

Statistically significant (P\<0.05).
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